Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769352 · ClinicalTrials.gov registry record · Phase 2
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
A Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME), sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01769352: Completed Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME), sponsored by Johns Hopkins University.
NCT01769352 is a Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME) that has completed, run by Johns Hopkins University. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769352, a Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME), has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
Primary Outcome
Mean change in best-corrected visual acuity (Letter Score) at Week 12 from Baseline. The Early Treatment of Diabetic Retinopathy Study (ETDRS) score is measured on a scale from 5 to 100. The higher the score on this scale, the better is the patients vision.
Conditions Studied
Interventions
- DRUG PredA + Kelac
Study Locations (1)
Maryland
- Wilmer Eye Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT01769352 record still lists
NCT01769352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Post-surgical Cystoid Macular Edema (PSCME) appearing as the primary indexed condition, and to 1 intervention - of which PredA + Kelac is the first listed.
NCT01769352 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01769352 about?
NCT01769352 is a clinical study titled "Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)". The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
What is the current status of trial NCT01769352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-08. Estimated completion is 2016-04.
What conditions does trial NCT01769352 study?
This clinical trial studies the following conditions: Post-surgical Cystoid Macular Edema (PSCME).
What interventions are being tested in trial NCT01769352?
The interventions under investigation include: PredA + Kelac (DRUG).
Who is sponsoring clinical trial NCT01769352?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769352 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01769352's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia